Activities of colistin- and minocycline-based combinations against extensive drug resistant Acinetobacter baumannii isolates from intensive care unit patients

Table 1 Acinetobacter baumannii isolates in this study and their MICs

Isolates	Infection	Sample	Clonotype	COL (μg/mL)	MEM (μg/mL)	MINO (μg/mL)	RFP (μg/mL)
09-95	VAP	Sputum	I	0.25	32	4	4
09-154	VAP	Sputum	I	0.25	16	4	8
09-1769	VAP	Sputum	II	0.5	64	8	4
09-1782	VAP	Sputum	I	0.5	16	4	8
09-2092	VAP	Sputum	I	0.25	128	8	4
09-2221	VAP	Sputum	I	0.5	64	4	4
09-2902	CB	Sputum	III	0.5	16	4	4
10-39	CB	Sputum	I	0.5	64	2	8
10-161	CB	Sputum	I	0.25	64	2	4
10-415	II	CSF	I	0.5	64	2	4
10-533	VAP	Sputum	I	0.25	16	4	8
10-548	HAP	Sputum	IV	0.5	64	4	16
10-584	VAP	Sputum	IV	0.5	64	4	8
10-617	CB	Sputum	IV	0.5	32	2	8

MIC = minimum inhibitory concentration, VAP = ventilator-associated pneumonia, HAP = hospital-acquired pneumonia, CB = colonized bacteria, II = intracranial infection, CSF = cerebrospinal fluid, COL = colistin (breakpoint = 2 μg/mL), MEM = meropenem (breakpoint = 16 μg/mL), MINO = minocycline (breakpoint = 16 μg/mL), RFP = rifampicin (no breakpoint is available).

ISSN: 1471-2334